Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Combination of Tenaya’s HDAC6 inhibitors with Empagliflozin Shows Additive Benefits in Preclinical HFpEF Model and Highlights Differentiated Mechanism of Action
News | Heart Failure
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

October 11, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 11, 2023
Home
Feature | Cardiovascular Clinical Studies | Christine Book
“One on One” with Christine Seidman, MD, FACC, on Hypertrophic Cardiomyopathy

October 11, 2023 — To gain the latest insight into genetic research for the treatment of hypertrophic cardiomyopathy ...

Home October 10, 2023
Home
REBALANCE-HF early feasibility trial met objective of identifying responder group with demonstrated benefits in heart function, hemodynamics, and physical activity at 6 months
News
Late-Breaking Data Confirms Safety of Axon Therapies' Innovative Heart Failure Procedure and Identifies Patients Most Likely to Benefit from SAVM Therapy

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
The study marks a new standard for inclusive medicine with recruitment for target demographics reaching over 3x the national average
News | Cardiovascular Clinical Studies
Hawthorne Effect Announces Monumental Diversity in Patient Recruitment Data for Valvular Heart Disease Study

October 10, 2023 — Hawthorne Effect, a complete clinical trials solution, announced interim recruitment results for the  ...

Home October 10, 2023
Home
Primary endpoint, six-month clinical and imaging data from clinical trial of DESyne BDS Plus stent system evaluating safety and efficacy of localized delivery of anticoagulants and an anti-proliferative agent designed to reduce the implant thrombotic risk
News | Stents Drug Eluting
Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
The program is recommended by the Centers for Medicare and Medicaid services for patients who undergo heart valve repair or replacement
News | Heart Failure
TAVR: Less Than One-third of Patients Enter Cardiac Rehab After Heart Procedure

October 9, 2023 — The vast majority of people who have a minimally invasive heart valve replacement procedure do not ...

Home October 09, 2023
Home
Rejuvenate Bio announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways. RJB-0402 demonstrated efficacy in a mouse model of arrhythmogenic cardiomyopathy (ACM)
News | Sudden Cardiac Arrest
Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy

October 9, 2023 — Rejuvenate Bio announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key ...

Home October 09, 2023
Home
Endotronix announced FDA approval for the PROACTIVE-HF 2 IDE trial with the Cordella Sensor to expand market access and shared positive results from a substudy of their pivotal PROACTIVE-HF clinical trial. The company plans to share full results from the PROACTIVE-HF trial next year.
News | Cardiovascular Clinical Studies
Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial

October 9, 2023 — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment ...

Home October 09, 2023
Home
Retrospective study of over 18,000 drug-refractory AFib patients found those treated with catheter ablation had a 57% lower risk of developing heart failure compared to those receiving antiarrhythmic drugs 
News | Atrial Fibrillation
Biosense Webster Study Links Lower Risk of Heart Failure in Atrial Fibrillation Patients Treated with Catheter Ablation Compared to Antiarrhythmic Drugs

October 6, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home October 06, 2023
Home
According to new research published in Mayo Clinic Proceedings, calculating the patient's mean arterial pressure (AugMAP) is a simple and effective way to identify those patients who may benefit from more aggressive treatment strategies.
News | Structural Heart
Mayo Clinic Researchers Develop Calculation to Identify High-risk Moderate Aortic Stenosis Patients

October 5, 2023 — Mayo Clinic researchers have developed a calculation that can help identify moderate aortic stenosis p ...

Home October 05, 2023
Home
Beilinson Hospital in Israel used Nanox.AI’s HealthCCSng solution to conduct study on routine chest CT scans to assess impact of AI-based coronary artery calcium (CAC) measurements
News | Computed Tomography (CT)
Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs

September 29, 2023 —Nano-X Imaging, an innovative medical imaging technology company, today announced that HealthCCSng ...

Home September 29, 2023
Home
Application based on clinically meaningful results from the Phase 3 STELLAR trial
News | Cardiovascular Clinical Studies
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

September 28, 2023 — Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a ...

Home September 28, 2023
Home
Study participants may transition from the rivaroxaban arm to abelacimab in an extension study
News | Cardiovascular Clinical Studies
Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions

September 26, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for ...

Home September 26, 2023
Home
Feature | TCT
Cardiovascular Research Foundation Preps Program for Scientific Symposium, TCT 2023

September 26, 2023 — The Cardiovascular Research Foundation's (CRF) annual scientific symposium, the Transcatheter ...

Home September 26, 2023
Home
Videos | Pharmaceuticals
VIDEO, Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now